SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Speculating in Takeover Targets
CTG 7.960-0.4%Oct 22 4:00 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: richardred who wrote (2455)4/5/2011 12:12:51 PM
From: richardred  Read Replies (1) of 6087
 
Merck paying $430 million for Inspire
Merck buying Inspire Pharmaceuticals for $430 million

On Tuesday April 5, 2011, 10:43 am EDT

NEW YORK (AP) -- Merck & Co. said Tuesday it is buying Inspire Pharmaceuticals Inc. for about $430 million in a move to expand its product portfolio with treatments for eye conditions.

Inspire's key product is Azasite, which is a treatment for pinkeye cause by bacteria.

Merck, which is based in Whitehouse Station. N.J., agreed to pay $5 per share, a 26 percent premium to Inspire's closing price on Monday.

Shares of Inspire jumped 98 cents, or 24.6 percent, to $4.96 in morning trading, signaling that investors approve of the deal.

Inspire's board recommended that its shareholders tender their shares in the deal. Warburg Pincus Private Equity IX L.P., which owns about 28 percent of the outstanding shares of Raleigh, N.C,-based Inspire, intends to tender its shares.

Azasite had $13.2 million in revenue during the fourth quarter. Inspire also makes the dry-eye treatment Restasis, which is sold by Allergan, and Elestat, which treats itchiness caused by allergy-related pinkeye.

The company had overall revenue of $30.2 million during the fourth quarter. In January, it said it would cut 65 jobs, or 27 percent of its work force, and concentrate on eye care drugs after the failure of an experimental cystic fibrosis treatment. The move followed the failure of denufosol in a late-stage clinical trial. Denusofol was designed to treat cystic fibrosis, a genetic condition that causes thick mucus buildup in the lungs.

Shares of Merck fell 13 cents to $33.14 in morning trading.
finance.yahoo.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext